MKI67 and breast cancer: From the more than 20 years survival analyses, Boström and colleagues revealed that there were statistically significant differences in BC-specific survival among women with tumors with high versus low expression of MMP-1, tumor grade I versus III, triple-negative versus non-triple negative, basal-like versus non-basal-like tumors, and low versus high Bcl-2 and Ki-67 expressions.